Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature
TLDR
An overview of safety data for intravitreal injection of common anti-VEGF agents is provided and encouraging results in halting the disease and improving the vision are provided.Abstract:
Intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents is increasingly used for the treatment of a wide variety of retinal diseases, including age-related macular degeneration, diabetic retinopathy and retinal vascular occlusions, and retinopathy of prematurity. Despite encouraging results in halting the disease and improving the vision, intravitreal injection of anti-VEGF agents may be associated with systemic adverse events and devastating ocular complications. In this review, we provide an overview of safety data for intravitreal injection of common anti-VEGF agents.read more
Citations
More filters
Journal ArticleDOI
Aptamers as targeted therapeutics: current potential and challenges
Jiehua Zhou,John J. Rossi +1 more
TL;DR: This Review discusses challenges of clinical translation of therapeutic aptamers, highlighting recent clinical developments and technological advances that have revived the impetus for this promising class of therapeutics.
Journal ArticleDOI
Vision Loss after Intravitreal Injection of Autologous "Stem Cells" for AMD.
Ajay E. Kuriyan,Thomas A. Albini,Justin H. Townsend,Marianeli Rodriguez,Hemang K. Pandya,Robert Leonard,M. Brandon Parrott,Philip J. Rosenfeld,Harry W. Flynn,Jeffrey L. Goldberg +9 more
TL;DR: The patients' severe visual loss after the injection was associated with ocular hypertension, hemorrhagic retinopathy, vitreous hemorrhage, combined traction and rhegmatogenous retinal detachment, or lens dislocation.
Journal ArticleDOI
Angiogenesis and Inflammation Crosstalk in Diabetic Retinopathy
Margarida Capitão,Raquel Soares +1 more
TL;DR: It was found a mutual contribution between inflammation andAngiogenesis along the process, culminating in vasopermeability (diabetes macular edema) and/or pathological angiogenesis (proliferative diabetic retinopathy).
Journal ArticleDOI
Diabetic macular oedema
TL;DR: Emerging therapeutic strategies include improving efficacy and duration of VEGF suppression, targeting alternative pathways such as inflammation, the kallikrein-kinin system, the angiopoietin-Tie2 system, and neurodegeneration, and using subthreshold and targeted laser therapy.
Journal ArticleDOI
Glaucoma: the retina and beyond.
Benjamin M. Davis,Laura Crawley,Milena Pahlitzsch,Fatimah Zara Javaid,Maria Francesca Cordeiro,Maria Francesca Cordeiro +5 more
TL;DR: The current understanding of the potential mechanisms underlying RGC and axonal loss in glaucoma is outlined, and an overview of recent developments in techniques for monitoring RGC health is provided, including recent progress towards the development of RGC specific contrast agents.
References
More filters
Journal ArticleDOI
Ranibizumab for Diabetic Macular Edema: Results from 2 Phase III Randomized Trials: RISE and RIDE
Quan Dong Nguyen,David M. Brown,Dennis M. Marcus,David S. Boyer,Sunil S. Patel,Leonard Feiner,Andrea Gibson,Judy P. Sy,Amy Chen Rundle,J Jill Hopkins,Roman G. Rubio,Jason S. Ehrlich +11 more
TL;DR: Ranibizumab rapidly and sustainably improved vision, reduced the risk of further vision loss, and improved macular edema in patients with DME, with low rates of ocular and nonocular harm.
Journal ArticleDOI
Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study.
David M. Brown,Peter A. Campochiaro,Rishi P. Singh,Zhengrong Li,Sarah Gray,Namrata Saroj,Amy Chen Rundle,Roman G. Rubio,Wendy Yee Murahashi +8 more
TL;DR: Intraocular injections of 0.3 mg or 0.5 mg ranibizumab provided rapid improvement in 6-month visual acuity and macular edema following CRVO, with low rates of ocular and nonocular safety events.
Journal ArticleDOI
Arterial Thromboembolic Events in Patients with Metastatic Carcinoma Treated with Chemotherapy and Bevacizumab
Frank A. Scappaticci,Jamey R. Skillings,S. N. Holden,Hans-Peter Gerber,Kathy D. Miller,Fairooz F. Kabbinavar,Emily K. Bergsland,James Ngai,Eric Holmgren,Jiuzhou Wang,Herbert Hurwitz +10 more
TL;DR: Combination treatment with bevacizumab and chemotherapy, compared with chemotherapy alone, was associated with an increased risk of arterial thromboembolism but not venous thrombosis, and Baseline or on-study aspirin use wasassociated with modest increases in grade 3 and 4 bleeding events.
Journal ArticleDOI
Ranibizumab for Macular Edema following Branch Retinal Vein Occlusion
Peter A. Campochiaro,Jeffrey S. Heier,Leonard Feiner,Sarah Gray,Namrata Saroj,Amy Chen Rundle,Wendy Yee Murahashi,Roman G. Rubio +7 more
TL;DR: Intraocular injections of 0.3 mg or 0.5 mg ranibizumab provided rapid, effective treatment for macular edema following BRVO with low rates of ocular and nonocular safety events and no new safety events were identified in patients with BRVO.
Journal ArticleDOI
Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES).
Lihteh Wu,Maria Ana Martinez-Castellanos,Hugo Quiroz-Mercado,J. Fernando Arevalo,Maria H. Berrocal,Michel Eid Farah,Mauricio Maia,Jose A. Roca,Francisco Rodríguez +8 more
TL;DR: Repeated intravitreal injections of either 1.25 mg or 2.5 mg of bevacizumab appears to be safe and well tolerated during the 1st year despite the limited follow-up, according to this retrospective, multicenter, open label, uncontrolled interventional case series.
Related Papers (5)
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
Jeffrey S. Heier,David M. Brown,Victor Chong,Jean-François Korobelnik,Peter K. Kaiser,Quan Dong Nguyen,Bernd Kirchhof,Allen C. Ho,Yuichiro Ogura,George D. Yancopoulos,Neil Stahl,Robert Vitti,Alyson J. Berliner,Yuhwen Soo,Majid Anderesi,Georg Groetzbach,Bernd Sommerauer,Rupert Sandbrink,Rupert Sandbrink,Christian Simader,Ursula Schmidt-Erfurth +20 more